Chronic hepatitis C: future treatment

References

• LauerGMWalkerBDHepatitis C Virus InfectionN Engl J Med2001345415211439948
   PubMed Web of Science ®Google Scholar
• PoordadFMcConeJJrBaconBRBoceprevir for untreated chronic HCV genotype 1 infectionN Engl J Med2011364131195120621449783
   PubMed Web of Science ®Google Scholar
• JacobsonIMMcHutchisonJGDusheikoGTelaprevir for previously untreated chronic hepatitis C virus infectionN Engl J Med2011364252405241621696307
   PubMed Web of Science ®Google Scholar
• ShermanKEFlammSLAfdhalNHResponse-guided telaprevir combination treatment for hepatitis C virus infectionN Engl J Med2011365111014102421916639
   PubMed Web of Science ®Google Scholar
• BaconBRGordonSCLawitzEBoceprevir for previously treated chronic HCV genotype 1 infectionN Engl J Med2011364131207121721449784
   PubMed Web of Science ®Google Scholar
• ZeuzemSAndreonePPolSTelaprevir for retreatment of HCV infectionN Engl J Med2011364252417242821696308
   PubMed Web of Science ®Google Scholar
• Wartelle-BladouCLe FolgocGBourliereMLecomteLHepatitis C therapy in non-genotype 1 patients: the near futureJ Viral Hepat201219852553622762136
   PubMed Web of Science ®Google Scholar
• CacoubPBourliereMLubbeJDermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antiviralsJ Hepatol201256245546321884670
   PubMed Web of Science ®Google Scholar
• SulkowskiMSRobertsSAfdhalNHRibavirin dose modification in treatment-naive and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in phase 3 studies [abstract]J Hepatol201256Suppl 2S459S460
   Web of Science ®Google Scholar
• PoordadFLawitzEReddyKRTiming and magnitude of ribavirin dose reduction do not impact sustained virologic response rates with boceprevir + peginterferon alfa-2b/ribavirin in the anemia management study in chronic HCV genotype 1 patients [abstract]Hepatology201256Suppl S1269A270A
   Google Scholar
• LawitzEZeuzemSNybergLMNelsonDRRossaroLBalartLABoceprevir combined with peginterferon alfa-2b/ribavirin in treatment-naive chronic HCV genotype 1 patients with compensated cirrhosis: sustained virologic response and safety subanalyses from the anemia management study [abstract]Hepatology201256Suppl216A
   Google Scholar
• CiesekSvon HahnTMannsMPSecond-wave protease inhibitors: choosing an heirClin Liver Dis201115359760921867939
   PubMed Web of Science ®Google Scholar
• FuscoDNChungRTNew protease inhibitors for HCV – help is on the wayJ Hepatol20115461087108921232563
   PubMed Web of Science ®Google Scholar
• AsselahTMarcellinPNew direct-acting antivirals’ combination for the treatment of chronic hepatitis CLiver Int201131Suppl 1687721205141
   PubMed Web of Science ®Google Scholar
• FriedMButiMDoreGJFlisiakRFerenciPJacobsonIMTMC 435 in combination with peginterferon and ribavirin in treatment naive HCV genotype 1 patients: Final results of the PILLAR phase IIB study [abstract]Hepatology201154Suppl S11429A
   Google Scholar
• ZeuzemSBergTGaneETMC435 in HCV genotype 1 patients who have failed previous pegylated interferon ribavirin treatment: Final SVR24 results of the ASPIRE trial [abstract]J Hepatol201256Suppl 2S1S222300459
   PubMed Web of Science ®Google Scholar
• SulkowskiMCeasuEAsselahTSilen-C1: sustained virologic response and safety of BI201335 combined with peginterferon alfa-2a and ribavirin in treatment naive patients with chronic genotype 1 infection [abstract]J Hepatol201154Suppl 1S27
   Google Scholar
• SulkowskiMBourliereMBronowickiJPSILEN-C2: Sustained virologic response and safety of BI 201335 combined with peginterferon alfa-2A and ribavirin in chronic HCV genotype 1 patients with non-response to P/R [abstract]J Hepatol201154Suppl 1S30
   Google Scholar
• EversonGCooperCHezodeCRapid and sustained achievement of undetectable HCV RNA during treatment with ritonavir-boosted danoprevir/PEGIFN alfa-2A/RBV in HCV genotype 1 or 4 patients: DAUPHINE week 12 interim analysis [abstract]J Hepatol201256Suppl 2S466
   Web of Science ®Google Scholar
• FeldJJJacobsonIJensenDMFosterGRPolSTamEUp to 100% SVR4 rates with ritonavir-boosted danoprevir, mericitabine and ribavirin with or without peginterferon alfa-2a in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study [abstract]Hepatology201256Suppl231A232A
   Google Scholar
• MannsMPGaneERodriguez-TorresMVaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase II studyHepatology201256388489322473713
   PubMed Web of Science ®Google Scholar
• LawitzERodriguez-TorresMStoehrAGaneEJSerfatyLBhanjaSA phase 2B study of MK 7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment [abstract]Hepatology2011541434A1435A
   Web of Science ®Google Scholar
• LawitzEPoordadFDeJesusEABT-450/ritonavir combined with pegylated interferon alpha-2A and ribavirin after 3 days monotherapy in genotype 1 HCV-infected treatment-naive subjects: 12 weeks sustained virologic response and safety results [abstract]J Hepatol201256Suppl 2S470
   Google Scholar
• PoordadFLalezariJLawitzEVan VlierbergheHShiffmanMLContinued high virologic response rates with ACH-1625 daily dosing plus pegIFN-alpha-2A in a 28 days and 12 week phase 2a trial [abstract]J Hepatol201256Suppl 2S455
   Web of Science ®Google Scholar
• BronowickiJ-PPolSThuluvathPAsunaprevir, an NS3 protease inhibitor in combination with peginterferon and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C infection [abstract]J Hepatol201256Suppl 2S431S432
   Google Scholar
• LokASGardinerDFLawitzEPreliminary study of two antiviral agents for hepatitis C genotype 1N Engl J Med2012366321622422256805
   PubMed Web of Science ®Google Scholar
• MorenoCBergTTanwandeeTA phase IIA, open label study to assess the antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6Hepatology201052Suppl749A750A
   Google Scholar
• HezodeCShiffmanMLCooperCRitonavir-boosted danoprevir plus peginterferon alfa-2a/ribavirin demonstrates up to 100% SVR24 with 12 or 24 weeks of total treatment in treatment-naive patients with genotype 4 infection in the DAUPHINE study [abstract]Hepatology201256Suppl557A
   Google Scholar
• BrainardDMPetryAVan DyckKSafety and antiviral activity of MK-5172 a novel HCV NS3/4A protease inhibitors with potent activity against known resistance mutants in genotype 1 and 3 HCV-infected patients [abstract]Hepatology201052Suppl706A707A
   Google Scholar
• BourliereMKhalounAWartelle-BladouCChronic hepatitis C: treatments of the futureClin Res Hepatol Gastroenterol201135Suppl 2S84S9522248700
   PubMedGoogle Scholar
• MembrenoFELawitzEJThe HCV NS5B nucleoside and non-nucleoside inhibitorsClin Liver Dis201115361162621867940
   PubMed Web of Science ®Google Scholar
• WedemeyerHJensenDHerringRJrEfficacy and safety of mericitabine in combination with PEG-IFN alfa-2A/RBV in G1/4 treatment naive HCV patients: Final analysis from the PROPEL study [abstract]J Hepatol201256Suppl 2S481S482
   Web of Science ®Google Scholar
• PockrosPJensenDTsaiNSVR-12 among G1/4 treatment-naive patients receiving mericitabine in combination with PEG-IFN alfa-2A/RBV: interim analysis from the JUMP-C study [abstract]J Hepatol201256Suppl 2S477S478
   Web of Science ®Google Scholar
• GaneEJRodriguez-TorresMNelsonDESustained virologic response following RG7128 1500 mg BID/PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior non responders [abstract]J Hepatol201052Suppl 1S16
   Google Scholar
• GaneEJStedmanCAHylandRHNucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis CN Engl J Med20133681344423281974
   PubMed Web of Science ®Google Scholar
• GaneEJStedmanCAHylandRHOnce daily sofosbuvir (GS-7977) plus ribavirin in patients with HCV genotypes 1, 2 and 3: The ELECTRON trialHepatology201256Suppl306A
   Google Scholar
• LalezariJLawitzERodriguez-TorresMOnce daily PSI-7977 plus PEGIFN/RBV in a phase 2B trial: Rapid virologic suppression in treatment-naive patients with HCV GT2/GT3 [abstract]J Hepatol201154Suppl 1S28
   Web of Science ®Google Scholar
• LawitzEGaneEStedmanCPSI-7977 PROTON and ELECTRON: 100% concordance of SV4 with SVR24 in HCV GT1, GT2 and GT3 [abstract]J Hepatol201256Suppl 2S4
   Web of Science ®Google Scholar
• HassaneinTLawitzECrespoIOnce daily sofosbuvir (GS-7977) plus PEG/RBV: high early response rates are maintained during post-treatment follow-up in treatment naive patients with HCV genotype 1, 4 and 6 infection in the ATOMIC study [abstract]Hepatology201256Suppl307A
   Google Scholar
• LarreyDLohseAWde LedinghenVRapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirinJ Hepatol2012571394622414766
   PubMed Web of Science ®Google Scholar
• JacobsonIPockrosPJLalezariJVirologic response rates following 4 weeks of filibuvir in combination with pegylated interferon alfa-2A and ribavirin in chronically-infected HCV genotype-1 patients [abstract]J Hepatol201052Suppl 1S465
   Google Scholar
• Rodriguez-TorresMLawitzEConwayBSafety and antiviral activity of the HCV non-nucleoside polymerase inhibitor VX-222 in treatment-naive genotype 1 HCV infected patients [abstract]J Hepatol201052Suppl 1S14
   Web of Science ®Google Scholar
• LawitzERodriguez-TorresMRustgiVKSafety and antiviral activity of ANA 598 in combination with pegylated interferon alfa-2A plus ribavirin in treatment-naive genotype 1 chronic HCV patients [abstract]Hepatology201052Suppl334A335A
   Google Scholar
• PoordadFLawitzEDeJesusEABT-072 or ABT-333 combined with pegylated interferon and ribavirin after 3 days monotherapy in HCV genotype 1 infected treatment-naive subjects: 12 week sustained virologic response and safety results [abstract]J Hepatol201256Suppl 2S478
   Web of Science ®Google Scholar
• LawitzEJacobsonIGodofskyEA phase 2B trial comparing 24 to 48 weeks treatment with tegobuvir (GS-9190)/PEG/RBV to 48 weeks treatment with PEG/RBV for chronic genotype 1 HCV infection [abstract]J Hepatol201154Suppl 1S181
   Web of Science ®Google Scholar
• Suk-Fong LokAHCV NS5A inhibitors in developmentClin Liver Dis20131711112123177287
   PubMed Web of Science ®Google Scholar
• HezodeCHirschfieldGMGhesquiereWDaclatasvir an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment naive HCV genotype 1or 4 subjects: phase 2b COMMAND-1 SVR12 results [abstract]Hepatology201256Suppl553A
   Google Scholar
• RatziuVGadanoAPolSTriple therapy with daclatasvir, peginterferon alfa-2a and ribavirin in HCV infected prior null and partial responders: 12 weeks results of phase 2b COMMAND-2 trial [abstract]J Hepatol201256Suppl 2S478S479
   Web of Science ®Google Scholar
• DoreGJLawitzEHezodeCTwelve or 16 week treatment with daclatasvir combined with peginterferon alfa and ribavirin for hepatitis C virus genotype 2 or 3 infection: COMMAND GT2/3 study [abstract]Hepatology201256Suppl558A559A
   Google Scholar
• LokASGardinerDFHezodeCSustained virologic response in chronic HCV genotype 1-infected null responders with the combination of daclatasvir and asunaprevir with or without peginterferon alfa-2a/ribavirin [abstract]Hepatology201256Suppl230A
   Google Scholar
• SulkowskiMSGardinerDFRodriguez-TorresMHigh rate of sustained virologic response with all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (Nucleotide NS5B inhibitor) with or without ribavirin, in treatment-naive patients chronically infected with HCV genotype 1,2 or 3 [abstract]Hepatology201256SupplLB-2
   Google Scholar
• SullivanGJRodriguez-TorresMLawitzEABT-267 combined with pegylated interferon alpha-2A and ribavirin in genotype 1 HCV-infected treatment-naive subject: 12 week antiviral and safety analysis [abstract]J Hepatol201256Suppl 2S480
   Web of Science ®Google Scholar
• SulkowskiMSRodriguez-TorresMLawitzEHigh sustained virologic response rate in treatment-naive HCV genotype 1A and 1B patients treated for 12 weeks with an interferon-free all-oral quad regimen: interim results [abstract]J Hepatol201256Suppl 2S560
   Google Scholar
• FlisiakRHorbanAGallayPThe cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virusHepatology200847381782618302285
   PubMed Web of Science ®Google Scholar
• MembrenoFEEspinalesJCLawitzEJCyclophilin inhibitors for hepatitis C therapyClin Liver Dis20131712913923177289
   PubMed Web of Science ®Google Scholar
• AlbertiAChuangWLFlisiakRAlisporivir plus peginterferon/ribavirin in HCV genotype 1 treatment-experienced patients achieves primary endpoint with superior efficacy at treatment week 12 compared to retreatment with PR [abstract]J Hepatol201256Suppl 2S553S554
   Web of Science ®Google Scholar
• PawlostkyJ-MSarinSKFosterGAlisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-GT2or GT3 patients: SVR12 results from VITAL-1 phase 2b study [abstract]J Hepatol201256Suppl 2S553
   Google Scholar
• WedemeyerHJanczewskaEWlodzimierzMSignificant improvement of complete EVR in HCVAC phase II clinical trial when adding TG4040 therapeutic vaccine to PEGIFN alfa-2A and ribavirin [abstract]J Hepatol201256Suppl 2S552
   Web of Science ®Google Scholar
• BiermerMSchlosserBFulopBHigh-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapyJ Viral Hepat201219854755322762138
   PubMed Web of Science ®Google Scholar
• MuirAJHillsonJAGrayTEPeginterferon Lambda-1a compared to peginterferon alpha-2a in treatment-naive patients with HCV genotype 1 or 4. SVR24 from EMERGE phase 2b [abstract]Hepatology201256Suppl299A
   Google Scholar
• GaneEJRobertsSKStedmanCAOral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trialLancet201037697511467147520951424
   PubMed Web of Science ®Google Scholar
• GaneEJPockrosPZeuzemSInterferon-free treatment with a combination of mericitabine and danoprevir/R with or without ribavirin in treatment-naive HCV genotype 1 infected patients [abstract]J Hepatol201256Suppl 2S555S556
   Web of Science ®Google Scholar
• ZeuzemSAsselahTAngusPEfficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infectionGastroenterology201114162047205521925126
   PubMed Web of Science ®Google Scholar
• ZeuzemSSorianoVAsselahTSVR4 and SVR12 with an interferon-free regimen of BI201335 and BI207127 +/− ribavirin in treatment naive patients with chronic genotype 1 HCV infection; interim results of SOUND-C2 [abstract]J Hepatol201256Suppl 2S45
   Google Scholar
• ZeuzemSSorianoVAsselahTInterferon-free combination treatment with HCV NS3/NS4 protease inhibitor BI201335 and the non nucleoside NS5B inhibitor BI 207127 with or without ribavirin: Final results of SOUND-C2 and predictors of response [abstract]Hepatology201256Suppl308A309A
   Google Scholar
• Di BisceglieAMNelsonDRGaneEVX-222 with TVR alone or in combination with peginterferon alfa-2a and ribavirin in treatment naive patients with chronic hepatitis C: ZENITH study interim results [abstract]J Hepatol201154Suppl 1S540
   Web of Science ®Google Scholar
• JacobsonISulkowskiMSGaneEJVX-222, telaprevir and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C: results of the ZENITH study interferon-free regimen [abstract]Hepatology201256Suppl308A
   Google Scholar
• ZeuzemSBuggischPAgarwalKDual, triple and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN/RBV for up to 28 days in treatment naive genotype 1 HCV subjects [abstract]Hepatology201052Suppl400A20232486
   PubMed Web of Science ®Google Scholar
• PoordadFLawitzEKowdleyKV12 week interferon-free regimen of ABT-450/R + ABT-333 + ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype 1 infected subjects and 47% of previous non-responders [abstract]J Hepatol201256Suppl 2S549S550
   Web of Science ®Google Scholar
• KowdleyKVLawitzEPoordadFA 12 week interferon-free treatment regimen with ABT-450/R, ABT-267, ABT-333 and ribavirin achieves a SVR12 rates (observed data) of 99% in treatment-naive patients and 93% in prior null responders with HCV genotype 1 infectionHepatology201256SupplLB-1
   Google Scholar
• LawitzEPoordadFKowdleyKVA 12 week interferon-free regimen of ABT-450/R, ABT-072 and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment-naive HCV IL28B-CC genotype1 infected subjects [abstract]J Hepatol201256Suppl 2S7
   Web of Science ®Google Scholar
• ChayamaKTakahashiSToyotaJDual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null respondersHepatology201255374274821987462
   PubMed Web of Science ®Google Scholar
• SulkowskiMGardinerDLawitzEPotent viral suppression with the all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (nucleotide NS5B inhibitor +/− ribavirin in treatment-naive patients with chronic HCV GT1,2, or 3 [abstract]J Hepatol201256Suppl 2S560
   Google Scholar
• EversonGTSimsKDRodriguez-TorresMAn interferon-free, ribavirin-free 12-week regimen of daclatasvir, asunaprevir and BMS-791325 yielded SVR4 of 94% in treatment-naive patients with genotype 1 chronic hepatitis C virus infection [abstract]Hepatology201256SupplLB-3
   Google Scholar
• NelsonDRGaneEJJacobsonIMVX222/Telaprevir in combination with peginterferon alfa-2A and ribavirin in treatment-naive genotype 1 HCV patients treated for 12 weeks: ZENITH study, SVR12 interil analysis [abstract]Hepatology201154Suppl1435A
   Google Scholar
• HajarizadehBGrebelyJDoreGJEpidemiology and natural history of HCV infectionNat Rev Gastroenterol Hepatol2013 [Epub ahead of print]
   Web of Science ®Google Scholar
• MarcellinPCheinquerHCurescuMWorldwide experience treating chronic hepatitis C with peginterferon alfa/ribavirin: Final results from 7163 naive mono-infected patients enrolled in the large multinational PROPHESYS cohort studyHepatology201154Suppl824A
   Google Scholar
• European Association for the Study of the LiverEASL Clinical Practice Guidelines: management of hepatitis C virus infectionJ Hepatol201155224526421371579
   PubMed Web of Science ®Google Scholar
• FosterGRHezodeCBronowickiJPTelaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infectionsGastroenterology20111413881889. e121699786
   PubMed Web of Science ®Google Scholar
• BenhamouYMoussalliJRatziuVActivity of telaprevir or in combination with peginterferon alfa-2a and ribavirin in treatment naive genotype 4 hepatitis C patients. Final results of study C210. [abstract]Hepatology201052Suppl719A720A
   Google Scholar
• SilvaMOKasserraCGuptaATreitelMHughesEO’MaraEAntiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3APASL Feb 17–20, 20112011101366
   Google Scholar
• SummaVLudmererSWMcCauleyJAMK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variantsAntimicrob Agents Chemother20125684161416722615282
   PubMed Web of Science ®Google Scholar
• PaeshuyseJKaulADe ClercqEThe non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitroHepatology200643476177016557546
   PubMed Web of Science ®Google Scholar
• MorenoCBergTTanwandeeTAntiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label studyJ Hepatol20125661247125322326470
   PubMed Web of Science ®Google Scholar
• PockrosPJensenDTsaiNSVR12 among G1/4 treatement naive patients receiving mericitabine in combination with PEG-IFN alfa-2a/ribavirin; Interim analysis from the JUMP-C study [abstract]J Hepatol201256Suppl 2S477S478
   Web of Science ®Google Scholar
• KowdleyKVLawitzECrespoIATOMIC: 97% RVR for PSI-7977 + PEG/RBV × 12 week regimen in HCV GT1: an end to response-guided therapy [abstract]?J Hepatol201256Suppl 2S122300459
   PubMed Web of Science ®Google Scholar
• HezodeCDorivalCZoulimFSafety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin in 455 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting [abstract]Hepatology201256Suppl217A
   Google Scholar
• CoillyARocheBBotta-FridlundDEfficacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: A first multicentric experience [abstract]J Hepatol201256Suppl 2S21
   Web of Science ®Google Scholar
• BourliereMWendtAFontaineHHezodeCPolSBronowickiJPHow to optimize HCV therapy in genotype 1 patients with cirrhosisLiver Int201333Suppl 1465523286846
   PubMed Web of Science ®Google Scholar
• LawitzERodriguez-TorresMCornpropstMTThe effect of hepatic impairment on the pharmacokinetics and antiviral activity of PSI-7977 in hepatitis C infected subjects treated for seven days [abstract]J Hepatol201256Suppl 2S445S446
   Web of Science ®Google Scholar
• SorianoVGaneEJAngusPWEfficacy and safety of the interferon-free combination of BI 201335 + BI 207127 with or without ribavirin in treatment-naive patients with HCV genotype 1 infection and compensated liver cirrhosis: results from the SOUND-C2 study [abstract]Hepatology201256Suppl 1234A
   Google Scholar
• MarcellinPMannsMJanczewskaE12 weeks response- guided treatment with the NS5A inhibitor, GS-5885, the NS3 protease inhibitor, GS-9451, plus pegylated interferon and ribavirin in treatment naive genotype 1 hepatitis C infected patientsJ Hepatol2013582S355
   Google Scholar
• ThompsonAHanSShiffmanM(2013) GS-5885 + GS- 9451 + PEGinterferon and ribavirin for six or twelve weeks achieves high SVR12 rates in treatment naive genotype1 IL28B CC patientsJ Hepatol2013582S29
   Web of Science ®Google Scholar
• EversonGDi BisceglieAVierlingJ2013Combination of the NS5A inhibitor GS-5885, the NS3 protease inhibitor GS-9451 and pegylated interferon plus riba- virin in treatment experienced patients with genotype 1 hepatitis C infectionJ Hepatol582S6
   Web of Science ®Google Scholar
• LawitzEGhalibRRodriguez-TorresMSVR4 results of a once daily regimen of simeprevir (TMC-435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV GT-1 null respon- ders. DDW Orlando May 18–21, 2013Gastroenterology Abstract Sa20131441374375
   Google Scholar
• MannsMMarcellinPPoordadFDe AraujoEButiMHorsmansYSimeprevir (TMC 435) with PEGinterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treat-ment-naive patients: results from Quest -2. A phase III trialJ Hepatol201358Suppl 1S568
   Web of Science ®Google Scholar
• JacobsonIDoreGFosterGFriedMRaduMRafalskiyVSimeprevir (TMC 435) with PEGinterferon/ribavirin for chronic HCV geno- type-1 infection in treatment naive patients: results from Quest-1, a phase III trialJ Hepatol201358Suppl 1S574.98
   Google Scholar
• ZeuzemSBergTGaneETMC435 in HCV genotype 1 patients who have failed previous pegylated interferon ribavirin treatment: final SVR24 results of the ASPIRE trialJ Hepatol201256Suppl 2S122300459
   PubMed Web of Science ®Google Scholar
• KowdleyKLawitzECrespoISofosbuvir with pegylated interferon alfa-2a and ribavirin for treat- ment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trialLancet20133812100210723499440
   PubMed Web of Science ®Google Scholar
• LawitzEGaneEStedmanCPSI-7977 proton and electron: 100% concordance of SV4 with SVR24 in HCV GT1, GT2 and GT3J Hepatol201256Suppl 2S4
   Web of Science ®Google Scholar
• LawitzELalezariJHassaneinTSofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with geno- types 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialLancet Infect Dis132013401408
   Web of Science ®Google Scholar
• LawitzEMangiaAWylesDSofosbuvir for previously untreated chronic hepatitis C infectionN Engl J Med20133681878188723607594
   PubMed Web of Science ®Google Scholar
• Rodriguez-TorresMLawitzEKowdleyKSofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trialJ Hepatol20135866366823183528
   PubMed Web of Science ®Google Scholar
• GaneEStedmanCHylandRNucleotide polymerase inhibitor sofosbuvir plus riba- virin for hepatitis CN Engl J Med2013368344423281974
   PubMed Web of Science ®Google Scholar
• GaneEStedmanCHylandRAll-oral sofosbuvir- based 12 week regimen for the treatment of chronic HCV infection: the Electron studyJ Hepatol201358Suppl. 1S6S7
   Web of Science ®Google Scholar
• LawitzEGhalibRRodriguez-TorresMSVR4 results of a once daily regimen of simeprevir (TMC-435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV GT-1 null respon-dersDDW Orlando20131821
   Google Scholar
• MarcellinPMannsMJanczewskaE12 weeks response-guided treatment with the NS5A inhibitor, GS-5885, the NS3 protease inhibitor, GS-9451, plus pegylated interferon and ribavirin in treatment naive genotype 1 hepatitis C infected patientsJ Hepatol201358Suppl 2S355
   Google Scholar
• ThompsonAHanSShiffmanMGS-5885 þ GS- 9451 þ PEG interferon and ribavirin for six or twelve weeks achieves high SVR12 rates in treatment naive genotype 1 IL28B CC patientsJ Hepatol201358Suppl 2S29
   Web of Science ®Google Scholar
• EversonGDi BisceglieAVierlingJCombination of the NS5A inhibitor GS-5885, the NS3 protease inhibitor GS-9451 and pegylated interferon plus riba-virin in treatment experienced patients with genotype 1 hepatitis C infectionJ Hepatol201358Suppl 2S6
   Web of Science ®Google Scholar
• SulkowskiMGardinerDLawitzEPotent viral suppression with the all-oral combination of daclatas-vir (NS5A inhibitor) and GS-7977 (nucleotide NS5B inhibitor þ/- ribavirin in treatment-naive patients with chronic HCV GT1,2, or 3J Hepatol201256S560
   Web of Science ®Google Scholar
• SulkowskiMGardinerDRodriguez-TorresMSustained virologic response with daclatasvir plus sofosbuvir with or without ribavirin in chronic HCV genotype 1 infected patients who previously failed tel-aprevir or borceprevirJ Hepatol201358Suppl 2S570
   Web of Science ®Google Scholar